Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
Fiche publication
Date publication
janvier 2020
Journal
European journal of heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B
Lien Pubmed
Résumé
To assess the prognostic value of mineralocorticoid receptor antagonist (MRA) initiation and change in serum potassium (K ) during follow-up in patients post-acute myocardial infarction with left ventricular dysfunction or chronic heart failure (HF) and reduced ejection fraction (HFrEF).
Mots clés
Heart failure with reduced ejection fraction, Hyperkalaemia, Hypokalaemia, Mineralocorticoid receptor antagonist, Risk score
Référence
Eur. J. Heart Fail.. 2020 Jan 9;: